TY - JOUR
T1 - Synthesis, inhibitory activity of cholinesterases, and neuroprotective profile of novel 1,8-naphthyridine derivatives
AU - De Los Ríos, Cristóbal
AU - Egea, Javier
AU - Marco-Contelles, José
AU - León, Rafael
AU - Samadi, Abdelouahid
AU - Iriepa, Isabel
AU - Moraleda, Ignacio
AU - Gálvez, Enrique
AU - García, Antonio G.
AU - López, Manuela G.
AU - Villarroya, Mercedes
AU - Romero, Alejandro
PY - 2010/7/22
Y1 - 2010/7/22
N2 - 1,8-Naphthyridine derivatives related to 17 (ITH4012), a neuroprotective compound reported by our research group, have been synthesized. In general, they have shown better inhibition of acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE) than most tacrine derivatives previously synthesized in our laboratory. The compounds presented an interesting neuroprotective profile in SH-SY5Y neuroblastoma cells stressed with rotenone/oligomycin A. Moreover, compound 14 (ethyl 5-amino-2-methyl-6,7,8,9- tetrahydrobenzo[b][1,8]naphthyridine-3-carboxylate) also caused protection in cells stressed with okadaic acid (OA) or amyloid β 1-42 peptide (Aβ1-42). Interestingly, compound 14 prevented the OA-induced PP2A inhibition, one of the enzymes implicated in t dephosphorylation. This compound also exhibited neuroprotection against neurotoxicity elicited by oxygen and glucose deprivation in hippocampal slices. Because these stressors caused neuronal damage related to physiopathological hallmarks found in the brain of Alzheimer's disease (AD) patients, we conclude that compound 14 deserves further in vivo studies in AD models to test its therapeutic potential in this disease.
AB - 1,8-Naphthyridine derivatives related to 17 (ITH4012), a neuroprotective compound reported by our research group, have been synthesized. In general, they have shown better inhibition of acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE) than most tacrine derivatives previously synthesized in our laboratory. The compounds presented an interesting neuroprotective profile in SH-SY5Y neuroblastoma cells stressed with rotenone/oligomycin A. Moreover, compound 14 (ethyl 5-amino-2-methyl-6,7,8,9- tetrahydrobenzo[b][1,8]naphthyridine-3-carboxylate) also caused protection in cells stressed with okadaic acid (OA) or amyloid β 1-42 peptide (Aβ1-42). Interestingly, compound 14 prevented the OA-induced PP2A inhibition, one of the enzymes implicated in t dephosphorylation. This compound also exhibited neuroprotection against neurotoxicity elicited by oxygen and glucose deprivation in hippocampal slices. Because these stressors caused neuronal damage related to physiopathological hallmarks found in the brain of Alzheimer's disease (AD) patients, we conclude that compound 14 deserves further in vivo studies in AD models to test its therapeutic potential in this disease.
UR - http://www.scopus.com/inward/record.url?scp=77954752031&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=77954752031&partnerID=8YFLogxK
U2 - 10.1021/jm901902w
DO - 10.1021/jm901902w
M3 - Article
C2 - 20575555
AN - SCOPUS:77954752031
SN - 0022-2623
VL - 53
SP - 5129
EP - 5143
JO - Journal of Medicinal Chemistry
JF - Journal of Medicinal Chemistry
IS - 14
ER -